Cargando…

Understanding the Mechanisms of Resistance to T Cell-based Immunotherapies to Develop More Favorable Strategies in Multiple Myeloma

Detalles Bibliográficos
Autores principales:	Ahn, Sungwoo, Leblay, Noémie, Neri, Paola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8171358/ https://www.ncbi.nlm.nih.gov/pubmed/34095759 http://dx.doi.org/10.1097/HS9.0000000000000575

Ejemplares similares

Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities
por: Leblay, Noémie, et al.
Publicado: (2020)

Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma
por: Lee, Holly, et al.
Publicado: (2023)

Immunotherapy Strategies Against Multiple Myeloma
por: Ma, Jing, et al.
Publicado: (2017)

Optimizing carfilzomib use in multiple myeloma treatment
por: Yoon, Sung-Soo
Publicado: (2019)

Steps towards a Multiple Myeloma Cure?
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Perspectives on the Risk-Stratified Treatment of Multiple Myeloma
por: Davies, Faith E., et al.
Publicado: (2022)

Understanding adverse events of immunotherapy: A mechanistic perspective
por: Burke, Kelly P., et al.
Publicado: (2020)

Neuroprotection induced by NMDA preconditioning as a strategy to understand brain tolerance mechanism
por: Constantino, Leandra C., et al.
Publicado: (2015)

Multiple myeloma in Korea: risk stratification and initial treatment
por: Yoon, Sung-Soo
Publicado: (2018)

Cardiovascular risk and aging: the need for a more comprehensive understanding
por: Trtica Majnarić, Ljiljana, et al.
Publicado: (2021)

Immunotherapy for Multiple Myeloma
por: Kröger, Nicolaus, et al.
Publicado: (2012)

Immunotherapy for Multiple Myeloma
por: Tamura, Hideto, et al.
Publicado: (2019)

Immunotherapy in Multiple Myeloma
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2020)

SARS-CoV-2 Vaccines in Patients With Multiple Myeloma
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Analysis of fluoxetine-induced plasticity mechanisms as a strategy for understanding plasticity related neural disorders
por: Rossi, Francesco Mattia
Publicado: (2016)

Response to “The Role of FcRn in the Pharmacokinetics of Biologics in Patients with Multiple Myeloma”
por: Xu, Xu Steven, et al.
Publicado: (2017)

ImmunoPET in Multiple Myeloma—What? So What? Now What?
por: Bailly, Clément, et al.
Publicado: (2020)

The Immune Microenvironment in Multiple Myeloma Progression at a Single-cell Level
por: Schinke, Carolina, et al.
Publicado: (2023)

The Role of Immunotherapy in Multiple Myeloma
por: Kocoglu, Mehmet, et al.
Publicado: (2016)

Editorial: Immunotherapy in Multiple Myeloma
por: Giuliani, Nicola, et al.
Publicado: (2019)

Introduction to “Immunotherapies for Multiple Myeloma”
por: Offidani, Massimo, et al.
Publicado: (2020)

Cellular immunotherapy in multiple myeloma
por: Vo, Manh-Cuong, et al.
Publicado: (2019)

Immunotherapy for the treatment of multiple myeloma
por: Boussi, Leora S., et al.
Publicado: (2022)

About the Need for a More Adequate Way to Get an Understanding of the Experiencing of Aesthetic Items
por: Carbon, Claus-Christian
Publicado: (2023)

Potential mechanisms of resistance to current anti-thrombotic strategies in Multiple Myeloma
por: Comerford, Claire, et al.
Publicado: (2022)

Major advances in the treatment of multiple myeloma in American Society of Hematology annual meeting 2020
por: Du, Jianhua, et al.
Publicado: (2021)

Novel Strategies for Immunotherapy in Multiple Myeloma: Previous Experience and Future Directions
por: Danylesko, Ivetta, et al.
Publicado: (2012)

Understanding the role of mechanics in nucleocytoplasmic transport
por: Andreu, Ion, et al.
Publicado: (2022)

Biological Characterization and Clinical Relevance of Circulating Tumor Cells: Opening the Pandora’s Box of Multiple Myeloma
por: Garcés, Juan-José, et al.
Publicado: (2022)

Charge Matters: Mutations in Omicron Variant Favor Binding to Cells
por: Nie, Chuanxiong, et al.
Publicado: (2022)

Multiple Myeloma as a Bone Disease? The Tissue Disruption-Induced Cell Stochasticity (TiDiS) Theory
por: Capp, Jean-Pascal, et al.
Publicado: (2020)

Development of management strategies for immune-related adverse effects of immunotherapies used in oncological treatment
por: Shankar, Abhishek, et al.
Publicado: (2021)

Myeloma Bone Disease
por: Sanderson, Ralph D, et al.
Publicado: (2009)

Development of Novel Immunotherapies for Multiple Myeloma
por: Al-Hujaily, Ensaf M., et al.
Publicado: (2016)

Is immunotherapy here to stay in multiple myeloma?
por: Rodríguez-Otero, Paula, et al.
Publicado: (2017)

BCMA-targeted immunotherapy for multiple myeloma
por: Yu, Bo, et al.
Publicado: (2020)

Immunotherapy of Multiple Myeloma: Promise and Challenges
por: Abramson, Hanley N
Publicado: (2021)

A critical role for the NFkB pathway in multiple myeloma
por: Demchenko, Yulia N., et al.
Publicado: (2010)

Developing next generation immunomodulatory drugs and their combinations in multiple myeloma
por: Thakurta, Anjan, et al.
Publicado: (2021)

Management of Sickle Cell Intrahepatic Cholestasis: An Argument in Favor of Automated Exchange Transfusion
por: Adkins, Brian D., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_h5elnj5pc7n6n8e08plc7fpa9o